Education
About Us
Working with TipRanks
Follow Us
SI-Bone Inc (SIBN)
NASDAQ:SIBN
SIBN Stock Chart & Stats
$13.83
$0.02(0.14%)
At close: 4:00 PM EST
$13.83
$0.02(0.14%)
Day’s Range― - ―
52-Week Range$12.50 - $21.89
Previous CloseN/A
Volume50.81K
Average Volume (3M)648.60K
Market Cap
$610.81M
Enterprise Value$569.68M
Total Cash (Recent Filing)$147.82M
Total Debt (Recent Filing)$1.12M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
May 11, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding44,165,287
10 Day Avg. Volume524,959
30 Day Avg. Volume648,599
Financial Highlights & Ratios
PEG Ratio1.10
Price to Book (P/B)4.83
Price to Sales (P/S)4.27
P/FCF Ratio-94.40
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue2.84
Enterprise Value/Gross Profit3.56
Enterprise Value/Ebitda-67.29
Forecast
1Y Price Target
$25.17Price Target Upside82.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.49
Revenue Forecast (FY)$229.86M
Bulls Say, Bears Say
Bulls Say
Clinical Evidence And Reimbursement SupportPublication of the STACI study in a peer‑reviewed journal and nationwide reimbursement for INTRA Ti strengthen clinical credibility and payment coverage, which could encourage interventional physicians to adopt metal implants and increase procedures in ambulatory surgical centers.
Financial Performance And ValuationAnalyst points to improving gross margins, positive free cash flow, and an attractive valuation versus peers as indicators that profitability upside and investor returns could materialize as the business scales.
Strategic Partnerships And International ExpansionAnalyst highlights the Smith & Nephew distribution agreement together with European regulatory clearance for TORQ as catalysts to expand access into trauma centers, accelerate international growth, and allow the direct sales team to focus on spine and interventional targets.
Bears Say
Execution Risk From Product Launches And UtilizationRevenue growth depends on successful upcoming product launches and greater procedure utilization, creating execution risk if new products fail to gain adoption as expected.
Guidance Uncertainty And Study Comparability LimitsAbsence of formal guidance increases near‑term forecast uncertainty, and the STACI trial's non‑head‑to‑head design limits direct comparisons between interventionalists and surgeons, reducing clarity around expected adoption trends.
Sales Execution SlowdownAnalyst notes a sequential slowdown in sales execution that has raised investor concern and could exert continued downward pressure on the stock if commercial momentum does not resume.
SI-Bone News
SIBN FAQ
What was SI-Bone Inc’s price range in the past 12 months?
SI-Bone Inc lowest stock price was $12.49 and its highest was $21.89 in the past 12 months.
What is SI-Bone Inc’s market cap?
SI-Bone Inc’s market cap is $610.81M.
When is SI-Bone Inc’s upcoming earnings report date?
SI-Bone Inc’s upcoming earnings report date is May 11, 2026 which is in 64 days.
How were SI-Bone Inc’s earnings last quarter?
SI-Bone Inc released its earnings results on Feb 23, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.126 by $0.086.
Is SI-Bone Inc overvalued?
According to Wall Street analysts SI-Bone Inc’s price is currently Undervalued.
Does SI-Bone Inc pay dividends?
SI-Bone Inc does not currently pay dividends.
What is SI-Bone Inc’s EPS estimate?
SI-Bone Inc’s EPS estimate is -0.19.
How many shares outstanding does SI-Bone Inc have?
SI-Bone Inc has 44,165,287 shares outstanding.
What happened to SI-Bone Inc’s price movement after its last earnings report?
SI-Bone Inc reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.126. Following the earnings report the stock price went down -2.113%.
Which hedge fund is a major shareholder of SI-Bone Inc?
Currently, no hedge funds are holding shares in SIBN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SI-Bone Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.17 (82.00% Upside)
$25.17 (82.00% Upside)
Blogger Sentiment
Bullish
SIBN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 662.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
54.93%
12-Months-Change
Fundamentals
Return on Equity
-12.91%
Trailing 12-Months
Asset Growth
3.20%
Trailing 12-Months
Company Description
SI-Bone Inc
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
SIBN Company Deck
SIBN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong operational and financial performance with record revenue, meaningful physician adoption gains, first full-year positive adjusted EBITDA, positive free cash flow in Q4, multiple reimbursement wins, product launches and a strategic distribution partnership. Remaining challenges include a still-present full-year net loss, conservative 2026 guidance reflecting product and partnership ramp timing, expected modest gross margin compression due to capacity investments, and limited international scale. On balance, the positives (high growth, improving profitability, cash generation, reimbursement wins and product pipeline momentum) significantly outweigh the risks and execution/timing uncertainties.View all SIBN earnings summariesSIBN Stock 12 Month Forecast
Average Price Target
$25.17
▲(82.00% Upside)
Technical Analysis
Ownership Overview
4.65% Insiders
29.13% Mutual Funds
15.11% Other Institutional Investors
40.30% Public Companies and
Individual Investors